Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.

Hollingshead MG, Stockwin LH, Alcoser SY, Newton DL, Orsburn BC, Bonomi CA, Borgel SD, Divelbiss R, Dougherty KM, Hager EJ, Holbeck SL, Kaur G, Kimmel DJ, Kunkel MW, Millione A, Mullendore ME, Stotler H, Collins J.

BMC Genomics. 2014 May 22;15:393. doi: 10.1186/1471-2164-15-393.

2.

Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.

Morrison BL, Mullendore ME, Stockwin LH, Borgel S, Hollingshead MG, Newton DL.

Cancer Med. 2013 Oct;2(5):687-700. doi: 10.1002/cam4.107.

3.

Trypsin-mediated ¹⁸O/¹⁶O labeling for biomarker discovery.

Ye X, Chan KC, Prieto DA, Luke BT, Johann DJ Jr, Stockwin LH, Newton DL, Blonder J.

Methods Mol Biol. 2013;1002:133-49. doi: 10.1007/978-1-62703-360-2_12.

PMID:
23625401
4.

The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response.

Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL.

Cancer Chemother Pharmacol. 2012 Jul;70(1):207-12. doi: 10.1007/s00280-012-1868-0. Erratum in: Cancer Chemother Pharmacol. 2012 Nov;70(5):763-4.

PMID:
22526412
5.

Challenges in plasma membrane phosphoproteomics.

Orsburn BC, Stockwin LH, Newton DL.

Expert Rev Proteomics. 2011 Aug;8(4):483-94. doi: 10.1586/epr.11.40. Review.

6.

ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.

Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH.

J Pediatr Hematol Oncol. 2011 Jul;33(5):360-8. doi: 10.1097/MPH.0b013e3182002f9f.

PMID:
21552147
7.

A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.

Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, Hollingshead MG, Newton DL.

Free Radic Biol Med. 2011 Jan 1;50(1):110-21. doi: 10.1016/j.freeradbiomed.2010.10.696.

8.

Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.

Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL.

Int J Cancer. 2010 Dec 1;127(11):2510-9. doi: 10.1002/ijc.25499.

9.

Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.

Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG, Newton DL.

J Proteome Res. 2010 Aug 6;9(8):4016-27. doi: 10.1021/pr100194d. Erratum in: J Proteome Res. 2011 Apr 1;10(4):2128.

10.

Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH.

J Pediatr Hematol Oncol. 2009 Aug;31(8):561-70. doi: 10.1097/MPH.0b013e3181a6e043.

11.

Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.

Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM, Newton DL, Bumke MA.

Int J Cancer. 2009 Sep 15;125(6):1266-75. doi: 10.1002/ijc.24496. Erratum in: Int J Cancer. 2010 Dec;127(11):E1. Bumke, Maja A [added].

12.

Anti-CD22 Onconase: preparation and characterization.

Newton DL, Stockwin LH, Rybak SM.

Methods Mol Biol. 2009;525:425-43, xiv. doi: 10.1007/978-1-59745-554-1_22.

PMID:
19252847
13.

ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.

Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL.

BMC Cancer. 2009 Feb 20;9:63. doi: 10.1186/1471-2407-9-63.

14.

Gene expression profiling of alveolar soft-part sarcoma (ASPS).

Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, Shoemaker RH.

BMC Cancer. 2009 Jan 15;9:22. doi: 10.1186/1471-2407-9-22.

15.

Proteomic analysis identifies oxidative stress induction by adaphostin.

Stockwin LH, Bumke MA, Yu SX, Webb SP, Collins JR, Hollingshead MG, Newton DL.

Clin Cancer Res. 2007 Jun 15;13(12):3667-81.

16.

Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma.

Stockwin LH, Blonder J, Bumke MA, Lucas DA, Chan KC, Conrads TP, Issaq HJ, Veenstra TD, Newton DL, Rybak SM.

J Proteome Res. 2006 Nov;5(11):2996-3007.

PMID:
17081051
17.

Antibodies as therapeutic agents: vive la renaissance!

Stockwin LH, Holmes S.

Expert Opin Biol Ther. 2003 Oct;3(7):1133-52. Review.

PMID:
14519077
18.

Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies.

Pandha HS, Stockwin LH, Eaton J, Clarke IA, Dalgleish AG, Todryk SM, Blair GE.

Prostate Cancer Prostatic Dis. 2003;6(1):6-11. Erratum in: Prostate Cancer Prostatic Dis. 2003;6(2):198.

PMID:
12664058
19.

The role of therapeutic antibodies in drug discovery.

Stockwin LH, Holmes S.

Biochem Soc Trans. 2003 Apr;31(2):433-6. Review.

PMID:
12653655
20.

Engineered expression of the Coxsackie B and adenovirus receptor (CAR) in human dendritic cells enhances recombinant adenovirus-mediated gene transfer.

Stockwin LH, Matzow T, Georgopoulos NT, Stanbridge LJ, Jones SV, Martin IG, Blair-Zajdel ME, Blair GE.

J Immunol Methods. 2002 Jan 1;259(1-2):205-15.

PMID:
11730855
Items per page

Supplemental Content

Loading ...
Support Center